Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Gross Profit: 2016-2025

Historic Gross Profit for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $24.2 million.

  • UroGen Pharma's Gross Profit rose 6.39% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.9 million, marking a year-over-year increase of 5.23%. This contributed to the annual value of $81.5 million for FY2024, which is 11.13% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Gross Profit is $24.2 million, which was up 17.13% from $20.7 million recorded in Q2 2025.
  • UroGen Pharma's Gross Profit's 5-year high stood at $24.2 million during Q3 2025, with a 5-year trough of $6.6 million in Q1 2021.
  • For the 3-year period, UroGen Pharma's Gross Profit averaged around $19.8 million, with its median value being $19.6 million (2024).
  • Data for UroGen Pharma's Gross Profit shows a peak YoY surged of 220.65% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows UroGen Pharma's Gross Profit stood at $14.6 million in 2021, then grew by 8.53% to $15.8 million in 2022, then surged by 34.21% to $21.2 million in 2023, then climbed by 4.00% to $22.1 million in 2024, then rose by 6.39% to $24.2 million in 2025.
  • Its Gross Profit stands at $24.2 million for Q3 2025, versus $20.7 million for Q2 2025 and $17.9 million for Q1 2025.